Article:Molecular Mechanisms Underlying Curcumin-Mediated Therapeutic Effects in Type 2 Diabetes and Cancer. (5884026)

From ScienceSource
Jump to: navigation, search

This page is the ScienceSource HTML version of the scholarly article described at Its title is Molecular Mechanisms Underlying Curcumin-Mediated Therapeutic Effects in Type 2 Diabetes and Cancer. and the publication date was 2018-03-20. The initial author is Marzena Wojcik.

Fuller metadata can be found in the Wikidata link, which lists all authors, and may have detailed items for some or all of them. There is further information on the article in the footer below. This page is a reference version, and is protected against editing.

Converted JATS paper:

Journal Information

Title: Oxidative Medicine and Cellular Longevity

Molecular Mechanisms Underlying Curcumin-Mediated Therapeutic Effects in Type 2 Diabetes and Cancer

  • Marzena Wojcik
  • Michal Krawczyk
  • Pawel Wojcik
  • Katarzyna Cypryk
  • Lucyna Alicja Wozniak

1Department of Structural Biology, Faculty of Biomedical Sciences and Postgraduate Education, Medical University of Lodz, ul. Zeligowskiego 7/9, 90-752 Lodz, Poland

2Department of Horticultural Crop Management and Nutrition, Research Institute of Horticulture, ul. Konstytucji 3 Maja 1/3, 96-100 Skierniewice, Poland

3Diabetology and Metabolic Diseases Department, Medical University of Lodz, ul. Pomorska 251, 92-213 Lodz, Poland

Publication date (collection): /2018

Publication date (epub): 3/2018


The growing prevalence of age-related diseases, especially type 2 diabetes mellitus (T2DM) and cancer, has become global health and economic problems. Due to multifactorial nature of both diseases, their pathophysiology is not completely understood so far. Compelling evidence indicates that increased oxidative stress, resulting from an imbalance between production of reactive oxygen species (ROS) and their clearance by antioxidant defense mechanisms, as well as the proinflammatory state contributes to the development and progression of the diseases. Curcumin (CUR; diferuloylmethane), a well-known polyphenol derived from the rhizomes of turmeric Curcuma longa, has attracted a great deal of attention as a natural compound with beneficial antidiabetic and anticancer properties, partly due to its antioxidative and anti-inflammatory actions. Although this polyphenolic compound is increasingly being recognized for its growing number of protective health effects, the precise molecular mechanisms through which it reduces diabetes- and cancer-related pathological events have not been fully unraveled. Hence, CUR is the subject of intensive research in the fields Diabetology and Oncology as a potential candidate in the treatment of both T2DM and cancer, particularly since current therapeutic options for their treatment are not satisfactory in clinics. In this review, we summarize the recent progress made on the molecular targets and pathways involved in antidiabetic and anticancer activities of CUR that are responsible for its beneficial health effects.


1. Introduction

Type 2 diabetes mellitus (T2DM) and cancer are growing at epidemic proportions resulting in significant economic, social, and health burden. Moreover, there is increasing incidence of obesity that is associated with an increased risk of developing T2DM and cancer [[1]]. Despite many efforts, the current therapeutic options for the treatment of T2DM and cancer remain far from satisfactory, primarily because of occurring serious side effects. Therefore, new therapeutic strategies are continually being searched to better treat the diseases. In the last years, a considerable attention has been focused on investigating functional properties of plant-derived compounds for their potential therapeutic purposes.

Curcumin (CUR) [1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] also called diferuloylmethane is a polyphenolic compound derived from the rhizomes of turmeric Curcuma longa that is well known not only as a spice in Asian cuisine and a food preservative agent but also as a phytochemical compound with the beneficial effects on several chronic disease states associated with inflammation and oxidative stress, including T2DM and cancer.

Oxidative stress is an imbalance between the formation of reactive oxygen species (ROS) and the antioxidant defense mechanisms in the cell which results in ROS-mediated peroxidation of membrane lipids and oxidative damage of DNA and proteins. There is now overwhelming evidence that CUR at low concentrations is a strong antioxidant that scavenges ROS, decreases lipid peroxidation, and stimulates antioxidant enzymes, including catalase, superoxide dismutase (SOD), glutathione peroxidase (GPx), and heme oxygenase 1 (OH1), thereby protecting cell constituents against oxidative damage [[2], [3]]. On the other hand, emerging findings indicate that CUR at higher concentrations possesses a prooxidant activity and induces cancer cell apoptosis, thus playing an important regulatory role in cell death during the neoplastic process [[4]].

As oxidative stress is closely associated with inflammation, there has been a growing interest in determining the anti-inflammatory potential of CUR. Currently, there are a large number of published reports confirming the direct action of CUR on the inflammatory response. Indeed, CUR exhibits a strong anti-inflammatory action by suppression of (i) inflammatory enzymes such as cyclooxygenase 2 (COX2) and lipoxygenase 5 (LOX5), that is, the key enzymes of the arachidonic acid pathways which is involved in the development of human cancer, and inducible nitric oxide synthase (iNOS) that catalyzes the oxidative deamination of l-arginine to produce NO, a potent proinflammatory mediator, (ii) inflammatory cytokines such as tumor necrosis factor α (TNFα), interleukin- (IL-) 1, 2, 6, 8, and 12, and monocyte chemoattractant protein 1 (MCP1), and (iii) transcription factors like activating protein 1 (AP1) and nuclear factor κB (NF-κB) [[5]]. The latter is considered not only as one of the most important regulators of proinflammatory gene expression but also as a key player in the development and progression of cancer since its constitutive activation is linked to the proliferation and survival of several types of cancer cells [[5]].

It is noteworthy that commercial CUR contains mixture of three curcuminoids consisting of approx. 77% diferuloylmethane (termed as CUR I), approx. 18% demethoxycurcumin (termed as CUR II), and approx. 5% bisdemethoxycurcumin (termed as CUR III) (Figure 1).

Although health benefits of CUR along with its good tolerance without any toxicity at high oral doses (up to 2.2 g of Curcuma extract containing 180 mg of curcumin/day for 4 months) have been demonstrated in patients with advanced refractory colorectal cancer [[6]], its poor bioavailability due to poor absorption, rapid metabolism, and systemic elimination markedly hampers its clinical application. To overcome these limitations, several different experimental approaches have been employed, including using adjuvants (e.g., piperine, quercetin, and resveratrol) [[7]] as well as nanoparticle-based delivery systems (e.g., liposomes, solid lipid nanoparticles, niosomes, polymeric nanoparticles, polymeric micelles, cyclodextrins, dendrimers, and silver and gold nanoparticles) [[8]]. The bioavailability of CUR may also be enhanced through the synthesis of CUR structural analogs [[9], [10]].

As a significant progress in elucidating the molecular mechanisms underlying antidiabetic and anticancer properties of CUR has been recently achieved, this review will be focused on presenting the molecular targets and pathways engaged in the beneficial effects of CUR.

2. Curcumin and T2DM

T2DM is a chronic, multifactorial, metabolic disorder characterized by hyperglycemia as a consequence of insulin deficiency (caused by decreased β-cell mass and the dysfunction of existing β-cells) and insulin resistance in the liver and peripheral tissues. T2DM is associated with microvascular complications (i.e., nephropathy, retinopathy, and neuropathy) and macrovascular complications (i.e., peripheral vascular disease, cerebrovascular disease, and cardiovascular disease) as well as an increased risk of developing certain types of malignancies, including liver, pancreas, colorectal, bladder, and breast cancers [[11]].

Obesity, defined as body mass index (BMI) ≥ 30 kg/m2, is an important risk factor for the development of T2DM and cardiovascular diseases [[12]]. The current evidence clearly indicates that weight loss as a result of lifestyle, pharmaceutical, and obesity surgical interventions reduces the risk of developing T2DM in the long term by approximately 32%, 10–74%, and 63%, respectively [[13]]. Although the pathophysiological mechanisms engaged in the progression of obesity to T2DM are complex and not completely understood, elevated plasma free fatty acids (FFAs), stemming from increased lipolysis in adipose tissue, as well as a low-grade inflammation state and increased oxidative stress have been recognized as the key contributors in this process [[12]].

The purpose of this section is to present an update on the antidiabetic mechanisms of CUR in various cellular and animal models of T2DM. Moreover, clinical efficacy and safety of CUR for the treatment and prevention of T2DM is described.

It is worth noting that the beneficial effects of CUR have also been proven in various diabetic complications, such as retinopathy, nephropathy, neuropathy, and cardiomyopathy, with the pathogenesis generally linked to hyperglycemia-induced oxidative stress and inflammation. As an overview of the molecular mechanisms targeted by CUR in the aforementioned diabetic complications has been given in several recent publications, this issue is beyond the scope of this review [[14]].

2.1. Molecular Aspects of Antidiabetic Action of CUR in Experimental Diabetic Models

The structural and functional defects in the insulin-producing and insulin-responsive tissues in the body have been implicated in the pathogenesis of T2DM. It is now generally accepted that CUR ameliorates the pathologic events in these tissues through diverse mechanisms and multiple molecular targets as shown in Figure 2.

2.1.1. Liver

The liver is the major organ responsible for maintaining glucose and lipid homeostasis under physiological conditions. Hence, the dysregulation of hepatic glucose and lipid metabolism may contribute to the development of T2DM. Several lines of evidence from in vitro experiments and diabetic animal models highlight a hepatoprotective function of CUR as a consequence of its ability to regulate glucose and lipid metabolism. Indeed, CUR has been shown to suppress hepatic glucose production by activating AMP-activated protein kinase (AMPK), a well-known metabolic stress sensing protein kinase that is activated in response to alterations in cellular energy levels [[15], [16]]. Furthermore, this polyphenolic compound may also inhibit the key regulatory enzymes for hepatic gluconeogenesis such as glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) [[15]]. Some animal studies have revealed that the CUR-mediated hypoglycemic effect may be associated with the enhanced activity of glucokinase (GK), the rate-limiting enzyme for the glycolytic pathway, as well as increased hepatic glycogen storage [[17]].

Several studies during the past decade have highlighted the key role of CUR in regulating hepatic lipid metabolism. In this context, CUR has been shown to reduce lipogenesis and lipid accumulation in the liver of insulin-resistant rodents, and these effects are associated with the downregulation of the two essential transcription factors involved in hepatic lipogenesis such as the sterol regulatory element-binding protein 1c (SREBP1c) and the carbohydrate response element-binding protein (ChREBP). In addition, CUR positively affects the activity of lipid-regulating enzymes, including fatty acid synthase (FAS), carnitine palmitoyltransferase 1 (CPT1), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), and acyl-CoA:cholesterol acyltransferase (ACAT) [[17], [18]].

It should be emphasized that CUR also ameliorates chronic liver diseases associated with T2DM, including hepatic steatosis. This disease is characterized by the excessive accumulation of hepatic triglycerides (TGs) resulting from an increased supply of FFAs from peripheral adipose tissue to the liver, enhanced de novo lipid synthesis via the lipogenic pathway, and impaired fatty acid oxidation [[19]]. There are now strong in vivo data supporting the protective role of CUR against hepatic steatosis. Indeed, this compound interferes with the mechanisms involved in abnormal fat accumulation in the liver through the downregulation of a lipogenic transcription factor SREBP1c and its several target enzymes, including acetyl-CoA carboxylase 1 (ACC1) and FAS, and the concomitant upregulation of PPARα via AMPK activation [[20]]. Another molecular target for CUR in preventing hepatic steatosis is protein-tyrosine phosphatase 1B (PTP1B), a negative regulator of insulin receptor (IR) signal transduction, whose overproduction has been found to associate with defective insulin and leptin signaling in the liver of rats with fructose-induced hepatic steatosis [[21]]. CUR downregulated hepatic PTP1B with the improvement of insulin and leptin signaling in these animals, as evidenced by enhanced phosphorylation of hepatic IR, insulin receptor substrate 1 (IRS1), and Janus-activated kinase-signal transducer 2 (JAK2) with a concomitant repression of signal transducer and activator of transcription 3 (STAT3) and suppressor of cytokine signaling 3 (SOCS3) and stimulation of protein kinase B (PKB, also known as Akt) and extracellular signal-regulated kinases 1/2 (ERK1/2) [[21]].

Since oxidative stress has been implicated in the pathogenesis of T2DM through its effect on peripheral tissues and the pancreatic β-cell, the hepatoprotective effect of CUR against the oxidative damage has been proven. In animals with experimental T2DM, CUR impaired hyperglycemia-induced oxidative stress through the normalization of the activity of hepatic antioxidant enzymes such as SOD, CAT, and GPx and a reduction of lipid peroxidation, as reflected by the decreased level of the end product of lipid peroxidation—malondialdehyde (MDA) [[17]].

As oxidative stress is closely linked to the inflammation in T2DM, the anti-inflammatory effects of CUR have also been observed in the liver of insulin-resistant animals, where dietary CUR reduced the activity of NF-κB and several inflammatory markers such as SOCS3, TNFα, MCP1, and chemokine (C-C motif) ligand-2 (CCR-2) [[22]].

2.1.2. Skeletal Muscle

The skeletal muscle is the major site of both glucose disposal and the mitochondrial capacity for energy expenditure, where glucose or lipids is/are used for energy production.

It has been becoming clear that hyperlipidemia, reflected by chronically increased plasma FFAs, leads to an increased uptake of FFAs by the muscle cell and the production of intramuscular fatty acid metabolites (i.e., long-chain acyl-CoA, diacylglycerol, TGs, and ceramides) which stimulate inflammatory cascade and inhibit insulin-stimulated glucose uptake, resulting in the development of skeletal muscles insulin resistance [[23]]. The cellular mechanisms underlying the accumulation of intracellular lipid intermediates have not been completely elucidated, but lower rates of fatty acid oxidation and higher rates of fatty acid uptake have been proposed as important factors associated with skeletal muscle insulin resistance [[23]]. CUR has been shown to ameliorate skeletal muscle insulin resistance in rodents with diet-induced insulin resistance via an increase of the uptake and oxidation of fatty acids [[24]]. These beneficial effects of CUR were strongly linked to the upregulation of fatty acid translocase (CD36), a fatty acid transporter protein implicated in the binding and transport of long-chain fatty acids, and CPT1, the enzyme involved in controlling the entry of long-chain fatty acyl-CoA into mitochondria. CUR also suppressed the ACC activity, a well-known enzyme that catalyzes the ATP-dependent carboxylation of acetyl-CoA to malonyl-CoA during the first step in fatty acid biosynthesis [[24]]. According to the hypothesis that CUR enhances fatty acid utilization as the energy source, and reduces lipid metabolites accumulation, Seo et al. [[17]] reported that CUR supplementation increases the skeletal muscle lipoprotein lipase (LPL) activity in insulin-resistant rodents. Currently, it is well established that LPL plays a rate-limiting role in TG-rich lipoprotein metabolism and its activity is associated with skeletal muscle insulin sensitivity [[25]].

In addition to weakening lipotoxicity in skeletal muscle, CUR may also exert beneficial effect on insulin-induced glucose transport in this tissue via the glucose transporter (GLUT) 4 system. It is known that the insulin-stimulated glucose uptake is impaired in patients with T2DM as a consequence of inhibiting GLUT 4 translocation to the cell membrane [[26]].

CUR has been shown to improve insulin sensitivity in muscle tissue of insulin-resistant rodents by an increase of the cellular glucose uptake as a result of the enhancement of GLUT4 translocation from intracellular compartments to the plasma membrane [[24], [27]]. In addition, the increased glucose oxidation and glycogen synthesis has also been found in the muscle cell [[24], [27]]. Importantly, the regulatory effect of CUR on glucose and lipid metabolism in skeletal muscle was mediated by the liver kinase B1- (LKB1-) AMPK signaling pathway, suggesting that AMPK might serve as a potential target of CUR to enhance insulin sensitivity in skeletal muscle [[24], [28]].

Compelling evidence indicates that a defect in the insulin signaling pathway at the IRS1 level is the primary post receptor abnormality resulting in skeletal muscle insulin resistance. The positive effect of CUR on the insulin signaling cascade by enhancing IRS1 tyrosine phosphorylation has been observed in insulin-resistant rodents [[29]]. In this study, CUR also attenuated the inflammatory signaling through suppression of NF-κB, COX2, and protein kinase C-theta (PKCθ). Furthermore, CUR decreased the oxidant status and increased the antioxidant status in the skeletal muscle, as evidenced by the reduced levels of MDA and total oxidant status (TOC) and increased muscle GPx expression. The latter effect was associated with impaired ERK1/2 and p38 activation [[29]]. Overall, these results indicate that CUR ameliorates skeletal muscle pathology via glucose and lipid metabolic changes as well as the improvement in antioxidant defense mechanism and anti-inflammatory effects.

2.1.3. Adipose Tissue

Adipose tissue is not only the main site of lipid storage but also an endocrine organ responsible for the synthesis and secretion of various bioactive molecules, collectively called adipokines or adipocytokines. Accumulating evidence indicates that adipose tissue dysfunction, characterized by abnormal adipokine production, increased FFA release and inflammation, plays an important role in the pathogenesis of T2DM [[30]]. As the expansion of adipose tissue leads to inflammatory and endoplasmatic reticulum (ER) stress responses, some studies have suggested that CUR might hold protective or ameliorating effects against these pathophysiologic events through its anti-inflammatory and antioxidative properties. In this regard, beneficial effects of CUR have been shown to associate with reduced macrophage infiltration of adipose tissue in obese mice. Furthermore, CUR improved the adipose tissue production of the anti-inflammatory adipokine adiponectin and several stress response proteins, including Sirtuin 1 (Sirt1), heat shock proteins 70 and 90 (Hsp70 and Hsp90), and forkhead transcription factor FKHR (Foxo1) [[22]]. Other studies in this area have confirmed the positive effect of CUR on adipose tissue inflammation by repressing several important mediators of the inflammatory response in adipocytes, including IL-1β, IL-6, TNFα, MCP1, and COX2. This protection effect of CUR stemmed from an inhibition of the NF-κB signaling pathway through preventing IκB degradation and, in turn, reducing NF-κB nuclear translocation in adipocytes [[31]].

It is well established that the development of obesity-related diseases is a result of the expansion of adipose tissue and the formation of new blood vessels for delivering oxygen and nutrients to adipocytes [[32]]. Thus, controlling fat mass is tightly associated with the modulation of both adipogenesis and angiogenesis. Several in vitro studies have found the antiadipogenic activity of CUR in 3T3-L1 cells, and AMPK as well as the canonical Wnt/β-catenin signaling and its downstream targets such as c-Myc and cyclin D1 have been implicated in this process [[33], [34]].

The hypothesis that blocking adipose tissue angiogenesis with CUR is a successful strategy for the therapy of obesity-related diseases has been proven by some studies. In fact, CUR inhibits adipose tissue neovascularization through suppression of vascular endothelial growth factor (VEGF) and its receptor VEGFR2 (i.e., the two major angiogenic factors involved in the stimulation of proliferation and migration of endothelial cells) and the stimulation of adipocyte energy metabolism, predominantly by AMPK activation [[33]].

In recent years, many studies have also focused on CUR as the so-called browning agent of adipose tissue that enhances heat production, thereby resulting in slimming. In this regard, CUR has been reported to induce the development of beige adipocytes in inguinal white adipose tissue (WAT) through the norepinephrine-β3 androgen receptor (AR) pathway, as reflected by beige cells emerging in inguinal WAT, and the increased expression of a panel of brown fat-specific genes in inguinal WAT [[35]].

2.1.4. Pancreatic β-Cells

Pancreatic β-cells are metabolic sensors which adjust insulin secretion to glucose levels in the bloodstream under physiological conditions. In subjects with T2DM, these cells are unable to produce a sufficient amount of insulin required for blood glucose control. In recent years, several studies have emphasized the importance of CUR in the enhancement of pancreatic β-cell function under diabetic conditions. In this context, Best et al. [[36]] demonstrated the stimulatory effect of CUR on β-cells that was associated with the depolarization of the cell membrane potential, the generation of electrical activity, and an increase in insulin release from these cells. The authors concluded that the aforementioned consecutive events induced by CUR may contribute to the enhancement of insulin action and subsequently a decrease of the blood glucose levels. Another proposed mechanism by which CUR may improve insulin secretion in islets includes the downregulation of cyclic nucleotide phosphodiesterases (PDEs), that is, the enzymes catalyzing the conversion of cAMP and cGMP into 5′-AMP and 5′-GMP, respectively. Thus, CUR may participate in the regulation of the cellular levels of the second messengers, and therefore, this compound should be considered as a PDE inhibitor to improve pancreatic β-cell function [[37]].

Other cellular mechanisms underlying the beneficial CUR action on β-cells have been proposed, including suppression of cell apoptosis, improvement of glucose-induced insulin secretory function by Akt activation, inhibition of nuclear translocation of Foxo1, impairment of ER stress, and promotion of mitochondrial survival pathway under elevated FFAs, especially the saturated FFAs such as palmitate [[38]].

2.2. The Effect of CUR on Metabolic Disturbances in Animal and Human Studies

2.2.1. Animal Models

In the last decade, antidiabetic properties of CUR have been extensively studied in various animal models of obesity (genetically and diet-induced) and T2DM (Table 1). The ability of this compound to improve glycemic status and insulin sensitivity has been demonstrated in high-fat-diet- (HFD-) fed C57BL/6J mice and C57BL/6J ob/ob mice with a spontaneous knockout mutation of the leptin gene that were treated with CUR-supplemented diet [[18], [22], [39]]. The insulin-sensitive action of CUR in these diabetic animals involved the improvement of insulin signaling in adipose tissue and hepatocytes as well as the attenuation of lipogenesis in the liver and the oxidative stress and inflammatory processes in adipose tissue. In addition, CUR supplementation was associated with decreased body weight or fat composition in HFD-fed mice [[18], [22], [39]]. As rosiglitazone is the antihyperglycemic drug that acts through the activation of peroxisome proliferator-activated receptor γ (PPARγ), that is, a number of the nuclear hormone receptor superfamily that regulates the transcription of several genes involved in adipocyte differentiation, glucose and lipid metabolism, and inflammation [[40]], its antidiabetic efficiency was compared to that of CUR in rodents with diet-induced insulin resistance [[41]]. Interestingly, both compounds exhibited a similar improvement in glucose tolerance, lipid profile, and insulin sensitivity. The latter effect of CUR was partially attributed to its anti-inflammatory action, as reflected by the reduced plasma TNFα levels as well as its antilipolytic action, as evidenced by decreased plasma FFA levels [[41]]. More recently, the positive effects of CUR on metabolic abnormalities associated with T2DM have been confirmed in high-fructose-fed Wistar rats, where CUR treatment attenuates insulin resistance and glucose intolerance as a consequence of its antioxidative and anti-inflammatory actions [[29]].

The beneficial effects of CUR have also been observed in other diabetic animal models such as KK-Ay mice, in which CUR reduced hyperglycemia through PPARγ activation [[42]], and C57BL/KsJ-db/db mice, in which CUR reduced insulin resistance and hyperglycemia as a result of the increased blood insulin concentration that subsequently leads to enhanced glycolysis and impaired gluconeogenesis in the liver and augmented LPL activity in skeletal muscle [[17]]. Of note, CUR was also able to reduce a hyperglycemia-induced oxidative stress in erythrocytes and the liver of db/db mice, pointing to its protective role against diabetic complications.

Taken together, animal studies are generally consistent in respect to the beneficial effect of CUR on insulin action in the liver, skeletal muscle, and adipose tissue in various models of insulin resistance.

2.2.2. Studies in Humans

Clinical implications of CUR, used in different doses and forms, have been demonstrated by the results obtained from only few small studies involving individuals with T2DM. In general, these studies have confirmed the beneficial effects of CUR on some metabolic and inflammatory indices in diabetic patients. In fact, curcuminoids supplementation (300 mg/day for 3 months) in overweigh/obese T2DM patients reduced the plasma levels of fasting blood glucose (FBG), glycosylated hemoglobin (HbA1c), FFAs, TGs, C-reactive protein (CRP), TNFα, IL-6, and adipocyte fatty acid-binding protein (A-FABP, also termed FABP4). The latter is a member of the cytosolic fatty acid-binding protein family that is highly produced by adipocytes and participates in intracellular fatty acid trafficking. In T2DM patients supplemented with curcuminoids, the plasma A-FABP level positively correlated with blood glucose, FFAs, and CRP levels, implying that a decrease in the plasma A-FABP level may be associated with the improvement of metabolic and inflammatory indices in diabetic subjects. Furthermore, curcuminoids increased plasma SOD activity and decreased insulin resistance index (HOMA-IR) in T2DM subjects [[43], [44]]. More recently, the efficacy of nano-CUR (as nano-micelle 80 mg/day for 3 months) on glucose and lipid parameters has been demonstrated in T2DM subjects, as evidenced by the decreased levels of HbA1c, glucose, and low-density lipoprotein cholesterol (LDL-C) and reduced body mass index (BMI) [[45]]. Of note, there is only a single randomized, double-blind, placebo-controlled clinical trial on the evaluation of a protective role of CUR against T2DM development in a prediabetic population, referring to individuals with elevated blood glucose levels but do not meet diagnostic criteria for T2DM. In this study, CUR supplementation was rather safe for prediabetic patients, leading to improved β-cell function, as reflected by an increase in homeostasis model of assessment for β-cell function (HOMA-B), reduction in the C-peptide level and HOMA-IR, and increased adiponectin level [[46]]. Adiponectin (AdipoQ), also known as adipocyte complement-related protein of 30 kDa (Acrp30) and gelatin-binding protein of 28 kDa (GBP28), is a well-known adipokine with insulin-sensitizing effect. Although the molecular mechanism(s) by which AdipoQ may impair insulin resistance is not completely clear, its role in the stimulation of fatty acid oxidation in the liver and muscle, activation of glucose uptake in muscle, and suppression of gluconeogenesis in the liver has been well documented [[47]].

3. Curcumin and Cancer

Cancer is a complex and multistep process that develops as a result of the accumulation of genetic and epigenetic alterations. These changes lead to sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis [[48]]. All these pathological events are linked to the coordinated action of numerous signaling pathways, creating a very complex but not yet fully understood intracellular picture of various networks associated with the development and progression of cancer. Knowledge about alterations in the expression and function of key components of these signal transduction pathways provides potential targets for anticancer therapy. Despite the introduction of approx. 150 anticancer cytotoxic and targeted drugs into clinics, the current treatment of cancers remains still far from satisfactory [[49], [50]]. Hence, there is imperative to develop safe and effective anticancer therapeutic strategies.

The chemotherapeutic potential of CUR has been shown in various types of cancers (i.e., multiple myeloma, lung, prostate, breast, ovarian, bladder, liver, gastrointestinal tract, pancreatic, colorectal epithelial cancer, and lymphomas) as a consequence of its inhibitory action on multiple carcinogenic signaling pathways. Although the exact molecular mechanisms underlying the anticancer CUR action remain unclear so far, multiple cellular targets for this polyphenol have been identified in numerous cancer model systems. Among them are the following: (i) transcription factors (e.g., AP1; STAT3; NF-κB; hypoxia-inducible factor 1α, HIF1α; nuclear factor erythroid 2- (NF-E2-) related factor, Nrf2; peroxisome proliferator-activated receptor γ, PPARγ), (ii) growth factors (e.g., fibroblast growth factor 2, FGF2; hepatocyte growth factor, HGF; platelet-derived growth factor, PDGF; VEGF; transforming growth factor β, TGFβ; angiopoietin 1 and 2, Ang 1 and 2), (iii) receptors (e.g., IL-8 receptor, IL-8R; epidermal growth factor receptor, EGFR), (iv) kinases (e.g., ERK; mitogen-activated protein kinase (MAPK); protein kinase A, PKA; PKB/Akt; PKC), (v) cytokines (e.g., TNFα; IL-1, -2, -5, -6, -8, -12, and -18; MCP1), (vi) enzymes other than kinases (e.g., COX2; iNOS; telomerase; matrix metalloproteinases, MMPs), and (vii) adhesion molecules (e.g., endothelial leukocyte adhesion molecule 1, ECAM1; intracellular adhesion molecule 1, ICAM1; vascular cell adhesion molecule 1, VCAM1). A detailed review of the entire list of intracellular biomolecules targeted by CUR has been recently published by Kunnumakkara et al. [[51]].

This section was designed to highlight the anticancer effects of CUR associated with its ability to modulate the activity of key factors in cellular signal transduction pathways which are involved in the initiation, promotion, and progression of tumors.

3.1. Proapoptotic Effects of CUR

Apoptosis is a tightly regulated process responsible for maintaining tissue homeostasis in multicellular organisms, and its functional disturbances contribute to oncogenic transformation and therapeutic resistance. Caspases are critical executioners of the apoptotic process consisted of the two major signaling pathways such as the intrinsic (i.e., mitochondria-dependent apoptosis) and extrinsic (i.e., mitochondria-independent apoptosis induced by death receptor activation) pathways. The latter is mediated through FasL and Fas/CD95 receptors followed by caspase 8 activation whereas the mitochondrial pathway is mediated through the change in the ratio of Bcl2-associated X (Bax)/B-cell lymphoma 2 (Bcl2) proteins, loss of mitochondrial membrane potential and then by caspase 9 activation, which leads to caspase 3 activation and ultimately nuclear DNA fragmentation [[52]].

In recent years, the proapoptotic effect of CUR has been documented in a variety of cancer cell lines and in vivo animal studies (Table 2). For example, CUR induced apoptosis via the upregulation of the proapoptotic Bax and the downregulation of the antiapoptotic proteins such as myeloid cell leukemia 1 (Mcl1) and Bcl2 in human melanoma cells. In addition, CUR activated caspase 3 and caspase 8 and deregulated the expression of several apoptosis-associated proteins such as NF-κB, p38 MAPK, and p53 [[53]]. In human nonsmall cell lung cancer, CUR stimulated the mitochondrial apoptosis pathway by reducing the mitochondrial membrane potential in a dose-dependent manner and subsequently releasing cytochrome c from mitochondria to the cytoplasm as a result of the Bax upregulation and the Bcl2 downregulation [[54]]. A recent in vitro model of lung cancer has been provided evidence for CUR-mediated apoptosis through the activation of the p53-miR192-5p/215/X-linked inhibitor of apoptosis (XIAP) pathway, suggesting a regulatory role of CUR as an epigenetic agent for miRNAs in suppression of human lung cancer [[55]]. The miRNAs are short and highly conserved noncoding RNAs involved in multiple steps in carcinogenesis, and miR-192-5p/215 have been recognized as putative tumor suppressors in nonsmall cell lung cancer [[55]]. The epigenetic activity of CUR on miRNAs has also been confirmed in MCF7 breast cancer cells, where CUR upregulated miRNA15 and miRNA16 and this effect was associated with the Bcl2 downregulation and apoptosis induction in these cells [[56]]. Furthermore, in MDA-MB-435 breast cancer cells, CUR suppressed the expression of histone methyltransferase, which is typically overexpressed in human breast cancers with poor prognosis, through the stimulation of the MAPK pathway, and this event was accompanied by G1 cell cycle arrest [[57]]. Of note, there is convincing evidence that there are other mechanisms underlying the growth inhibitory activity of CUR against human breast cancer, including suppression of the microtubule assembly dynamics linked to the activation of the mitotic checkpoint [[58]] and the Wnt/β-catenin signaling pathway that is an important regulator of tumor cell invasion and metastasis [[59]].

The oncostatic action of CUR on neoplastic cells may also result from its capability of stimulating ROS production in various malignant cancer cell lines. In support of this, Li et al. [[60]] demonstrated that CUR-mediated ROS overproduction in liver cancer cells upregulates the toll-like receptor 4 (TLR4), that is, a key player in the inflammatory process, which subsequently stimulates the myeloid differentiation primary response protein MyD88, a downstream adaptor molecule of TLR4, leading to apoptosis [[60]]. The relationship between CUR-mediated ROS generation and apoptosis was further confirmed in gastric cancer cells (where ROS induced the apoptosis signal-regulating kinase 1 (ASK1)/MAPK kinase (MKK) 4/c-Jun N-terminal kinase (JNK) signaling pathway) [[61]] and osteosarcoma cells (where ROS induced the mitochondrial cytochrome c/caspase 3 apoptotic pathway) [[62]].

The proapoptotic effect of CUR has also been largely attributed to its modulatory effect on the transcriptional factor NF-κB that is constitutively overexpressed in cancer. In melanoma cells, CUR inhibited NF-κB in a dose-dependent manner and, in turn, induced apoptosis [[63]]. More recently, Cao et al. [[64]] showed that CUR-mediated NF-κB suppression in giant cell tumor of bone leads to the inhibition of cell proliferation and promotion of apoptosis through the stimulation of the JNK signaling pathway.

In vitro studies have also proved that CUR may induce apoptosis in acute myeloid leukemia cells via a simultaneous attenuation of the two critical prosurvival signaling pathways such as the Akt/mammalian target of rapamycin (mTOR) pathway and the Raf/mitogen-activated signal-regulated protein kinase (MEK)/ERK pathway [[65]].

It is noteworthy that although many studies have been focused on the proapoptotic properties of CUR, other types of CUR-mediated cell death pathways, including autophagy, mitosis catastrophe, and paraptosis, have also been recognized in some experimental studies [[66]].

3.2. Anti-Invasion Effects of CUR

Several lines of evidence indicate that CUR does not only affect the tumor growth, but also inhibits the tumor development, primarily by suppressing MMPs, that is, zinc-dependent endopeptidases participating in the excessive degradation of the extracellular matrix (ECM) during tumor invasion and metastasis (Table 2). Indeed, CUR has been shown to repress the migration and invasion of tongue carcinoma cells through the downregulation of MMP10, which is usually increased in this type of cancer [[67]]. In breast cancer cells, CUR downregulated MMP9 by blocking the PKCα/MAPK/NF-κB/AP1 pathway (in the MCF7 cell line) or the TGFβ/Smad and TGFβ/ERK signaling pathways (in the MDA-MB-231 cell line) [[68], [69]]. CUR also downregulated MMP2/9 in endometrial carcinoma cells via suppressing the ERK signaling pathway [[70]]. Recently, the novel antimetastatic mechanism of CUR action in colon cancer has been proposed [[71]]. According to this, CUR can reduce the level of the active phosphorylated form of cortactin (i.e., the pTyr421), overexpressed in colon cancer cells, through a direct physical interaction with the nonreceptor type 1 protein-tyrosine phosphatase (PTPN1), leading to an increased PTPN1 activity and subsequently reduced cancer cell migration. Although the role of the PTPN1/cortactin axis has been identified in the mechanism of CUR-induced inhibition of colon cancer cell migration, additional studies are required to establish the mechanism by which CUR activates PTPN1. Moreover, verifying the significance of the PTPN1/cortactin pathway in cell metastasis of other cancers is needed.

3.3. Chemosensitizing Properties of CUR

An important aspect of the anticancer activity of CUR is its ability to sensitize cancer cells to chemotherapeutics, thereby enhancing the anticancer effect of chemotherapeutics and improves the efficacy of cancer treatment.

The synergistic effect of the combination of CUR with different anticancer drugs used widely in clinical practice (e.g., cisplatin, carboplatin, 5-fluorouracil (5-FU), gemcitabine, and paclitaxel) has been observed in various cancer types, including lung, breast, colon, pancreas, gastric, liver and prostate cancers [[72]]. Although the mechanism of CUR action as a chemosensitizer involves multiple targets participating in the survival signaling pathways, the transcription factor NF-κB appears to be one of crucial biomolecules targeting by CUR [[72]]. The phase II clinical trial has revealed that CUR intake (8 g per day) causes the NF-κB downregulation in peripheral blood mononuclear cells of patients with advanced pancreatic cancer and, moreover, the combination treatment of CUR with gemcitabine is safe in these patients [[73]]. In another related human study, an oral intake of CUR (8 g per day) in combination with gemcitabine-based chemotherapy resulted in a median survival time of 161 days and a 1-year survival rate of 19% for patients with pancreatic cancer, suggesting that CUR may potentiate traditional chemotherapeutic agent [[74]]. A good potential of CUR has also been found in combination with standard docetaxel chemotherapy in patients with advanced breast cancer and castration-resistant prostate cancer [[75], [76]]. According to, there are presently several interventional studies in various stages evaluating CUR as an adjunctive treatment for some cancer types. In these studies, CUR is used in combination with the following anticancer agents: (i) 5-FU in patients with chemoresistant metastatic colorectal cancer (NCT02724202; n = 14), (ii) tyrosine kinase inhibitors such as gefitinib (Iressa) and erlotinib (Tarceva) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NCT02321293; n = 20), (iii) docetaxel in patients with HER2 negative locally advanced or metastatic breast cancer (NCT00852332; n = 100), (iv) gemcitabine along with paclitaxel and metformin in patients with unresectable pancreatic cancer (NCT02336087; n = 21), and (v) irinotecan in patients with metastatic adenocarcinoma of the colon or rectum (NCT01859858; n = 23). These clinical trials are primarily concentrated on determining the feasibility, safety, and efficacy of CUR used in combination with the aforementioned anticancer agents. Of note, the effect of CUR on irinotecan pharmacokinetics was also investigated to better understand the interaction between CUR and the anticancer drug. Taken together, the findings obtained from these studies might lead to improved dosing guidelines and more effective treatment of different types of cancer with less toxicity.

3.4. Radiosensitizing Properties of CUR

CUR has also proven to be a radiosensitizer for cancer cells by the downregulation of different growth regulatory pathways and the protection of normal cells from radiotherapy-induced toxicity [[77]]. Apart from the ability of CUR to enhance the effect of radiation treatment on cancer cells, CUR also possesses the radioprotective properties. Recently, the double-blind, placebo-controlled clinical trial has provided the data supporting the radioprotective effect of CUR in patients with prostate cancer treated with radiotherapy. In this study, CUR supplementation (3 g per day) impaired the severity of radiotherapy related with urinary symptoms in patients with prostate cancer, thus improving their quality of life [[78]]. The radioprotective effect of CUR has also been observed in another randomized, double-blind, placebo-controlled clinical trial, where oral CUR (6 g per day) reduced radiation dermatitis severity in breast cancer patients receiving radiotherapy [[79]]. As radiation-induced dermatitis occurs in approx. 95% of patients receiving radiotherapy for breast cancer and, moreover, as there is no standard treatment for the prevention of radiation-induced dermatitis, CUR appears to be an effective protector against radiation-induced skin reactions in breast cancer patients receiving radiotherapy. However, due to a small group of the participants, further clinical trials with large groups of patients should be performed to confirm the long-term safety and effectiveness of CUR treatment in the radiotherapeutic strategy for breast cancer patients. Additionally, more molecular research is needed to identify the biological mechanisms involved in the radioprotective effect of CUR in breast cancer. It should be emphasized that there is also an ongoing randomized clinical trial (NCT00745134; focused on determining whether the combination of CUR with standard radiotherapy and chemotherapy (i.e., capecitabine) is able to shrink or slow the growth of rectal cancer as well as reduce some of the side effects of the radio- and chemotherapeutic approaches.

3.5. Nanoformulations of CUR

The low solubility and poor bioavailability of CUR, mainly due to intestinal and hepatic glucuronidation, limit its application as a therapeutic agent in clinical oncology. In 2004, Garcea et al. [[80]] reported that CUR consumption at a dosage of 450–3600 mg per day results in undetectable plasma CUR levels in patients with hepatic metastases from colorectal cancer. To overcome this issue and improve CUR pharmacokinetic properties and its anticancer therapeutic potential, various novel delivery systems have been developed in recent years, including liposomes, solid lipid nanoparticles, niosomes, polymeric nanoparticles, polymeric micelles, cyclodextrins, dendrimers, and silver and gold nanoparticles. A comprehensive characteristic of CUR nanoformulations in respect to their beneficial effects in drug delivery has been recently presented by Mehanny et al. [[8]] and is beyond the scope of this review. However, it should be highlighted that among numerous advanced drug delivery strategies for CUR, poly(d,l-lactic-co-glycolic acid) (PLGA) is currently one of the most commonly used polymers due its nontoxic, biodegradable, and nonimmunogenic nature. Furthermore, the nano-CUR-loaded PLGA has been shown to exhibit enhanced bioavailability up to 22-fold compared to conventional CUR in an experimental animal model [[81]]. More recently, CUR conjugated with PLGA has been reported to possess an improved sustainability, cellular uptake, and efficiency in suppressing cell proliferation and inducing apoptotic cell death signaling in human colon carcinoma cells compared to native CUR [[82]]. The enhanced anticancer efficacy of a PLGA-CUR formulation is in accordance with other studies demonstrating a higher effectiveness of PLGA-CUR than free CUR in repressing prostate cancer cell growth under in vitro and in vivo conditions. The mode of action of PLGA-CUR comprised the inhibition of cellular signaling molecules such as Akt and STAT3 and, in turn, the induction of apoptosis via the downregulation of the antiapoptotic proteins such as Bcl-xL and Mcl1 and the stimulation of the poly (ADP-ribose) polymerase (PARP) cleavage. In prostate cancer cells, PLGA-CUR also suppressed of the expression of AR and nuclear β-catenin. The latter is the major downstream effector of the canonical Wnt pathway and the AR coactivator in prostate cancer development. Furthermore, PLGA-CUR downregulated miR21 and upregulated miR205; thus, both miRNAs involved in prostate cancer progression and metastasis (Table 2) [[83]].

4. Conclusion

CUR is one of the most commonly studied natural compounds in respect to T2DM and cancer. A large body of evidence from preclinical studies indicates that CUR possesses a number of antidiabetic health benefits via attenuating hyperglycemia, hyperlipidemia, and insulin resistance. These positive effects of CUR appear to predominantly result from its pleiotropic effects on diverse molecular mechanisms associated with abnormal glucose and lipid metabolism, inflammation, and oxidative stress; thus, all the pathological changes occurred during the development and progression of T2DM. Of note, the promising antidiabetic effects of CUR found in cellular and animal models were also confirmed in few small clinical studies. Despite encouraging results, additionally large-scale, well-controlled trials regarding doses, effectiveness, and safety of CUR remain to be conducted.

In recent years, a significant research effort has also been focused on elucidating the signaling pathways involved in the oncostatic action of CUR. A great deal of experimental data obtained from in vitro and in vivo models of carcinogenesis support CUR as an effective regulator of cancer promotion and progression. The anticancer-promoting effects of CUR have largely been attributed to its ability to suppress cell growth, angiogenesis, and metastasis as well as to induce apoptosis in a variety of cancer types. Furthermore, the positive effects of the combined treatment of CUR with conventional chemotherapy drugs or radiotherapy should be considered as a subject of subsequent research, opening up new opportunities for effective intervention in cancer treatment. In spite of the beneficial biological activities of CUR, its poor bioavailability markedly limits its clinical application. To overcome this issue, various nanotechnology-based drug delivery systems have been developed and investigated in vitro and in vivo, giving satisfactory results. Importantly, CUR is safe and well tolerated in human clinical trials of cancer.



This work was supported in part by the Healthy Ageing Research Centre project (REGPOT-2012-2013-1, 7 FP) and grant from the Medical University of Lodz (Project no. 502-03/0-160-01/502-04-034 to Michal Krawczyk).


  1. E. J. GallagherD. LeRoithObesity and diabetes: the increased risk of cancer and cancer-related mortalityPhysiological Reviews201595372774810.1152/physrev.00030.20142-s2.0-8493143405626084689
  2. S. HewlingsD. KalmanCurcumin: a review of its’ effects on human healthFoods2017612p. 9210.3390/foods610009229065496
  3. G. S. JeongG. S. OhH.-O. PaeComparative effects of curcuminoids on endothelial heme oxygenase-1 expression: ortho-methoxy groups are essential to enhance heme oxygenase activity and protectionExperimental & Molecular Medicine200638439340010.1038/emm.2006.462-s2.0-3374869431416953118
  4. M. M. MansonInhibition of survival signalling by dietary polyphenols and indole-3-carbinolEuropean Journal of Cancer200541131842185310.1016/j.ejca.2005.05.0082-s2.0-2764450868216087329
  5. V. P. MenonA. R. SudheerAntioxidant and anti-inflammatory properties of curcuminAdvances in Experimental Medicine and Biology200759510512510.1007/978-0-387-46401-5_32-s2.0-8493443605717569207
  6. R. A. SharmaH. McLellandK. A. HillPharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancerClinical Cancer Research2001771894190011448902
  7. L. MasuelliE. di StefanoM. FantiniResveratrol potentiates the in vitro and in vivo anti-tumoral effects of curcumin in head and neck carcinomasOncotarget2014521107451076210.18632/oncotarget.25342-s2.0-8491693835525296980
  8. M. MehannyR. M. HathoutA. S. GeneidiS. MansourExploring the use of nanocarrier systems to deliver the magical molecule; curcumin and its derivativesJournal of Controlled Release201622513010.1016/j.jconrel.2016.01.0182-s2.0-8495551580326778694
  9. B. RajithaA. BelalcazarG. P. NagarajuInhibition of NF-κB translocation by curcumin analogs induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancerCancer Letters2016373222723310.1016/j.canlet.2016.01.0522-s2.0-8495867222626850372
  10. B. RajithaG. P. NagarajuW. L. ShaibNovel synthetic curcumin analogs as potent antiangiogenic agents in colorectal cancerMolecular Carcinogenesis201756128829910.1002/mc.224922-s2.0-8496468265227128654
  11. E. GiovannucciD. M. HarlanM. C. ArcherDiabetes and cancer: a consensus reportDiabetes Care20103371674168510.2337/dc10-06662-s2.0-7795551744120587728
  12. S. YaturuObesity and type 2 diabetesJournal of Diabetes Mellitus201114799510.4236/jdm.2011.14012
  13. L. S. AucottInfluences of weight loss on long-term diabetes outcomes: symposium on ‘diet and diabetes’Proceedings of the Nutrition Society2008671545910.1017/S00296651080060222-s2.0-3874915000418234132
  14. M. K. JeengerS. ShrivastavaV. G. YerraV. G. M. NaiduS. RamakrishnaA. KumarCurcumin: a pleiotropic phytonutrient in diabetic complicationsNutrition201531227628210.1016/j.nut.2014.06.0152-s2.0-8492089546625441584
  15. T. KimJ. DavisA. J. ZhangX. HeS. T. MathewsCurcumin activates AMPK and suppresses gluconeogenic gene expression in hepatoma cellsBiochemical and Biophysical Research Communications2009388237738210.1016/j.bbrc.2009.08.0182-s2.0-6924921636219665995
  16. N. B. RudermanD. CarlingM. PrentkiJ. M. CacicedoAMPK, insulin resistance, and the metabolic syndromeJournal of Clinical Investigation201312372764277210.1172/JCI672272-s2.0-8487962144223863634
  17. K. I. SeoM. S. ChoiU. J. JungEffect of curcumin supplementation on blood glucose, plasma insulin, and glucose homeostasis related enzyme activities in diabetic db/db miceMolecular Nutrition & Food Research2008529995100410.1002/mnfr.2007001842-s2.0-5494911952818398869
  18. W. ShaoZ. YuY. ChiangCurcumin prevents high fat diet induced insulin resistance and obesity via attenuating lipogenesis in liver and inflammatory pathway in adipocytesPLoS One201271, article e2878410.1371/journal.pone.00287842-s2.0-8485550388722253696
  19. J. RichardI. LingvayHepatic steatosis and type 2 diabetes: current and future treatment considerationsExpert Review of Cardiovascular Therapy20119332132810.1586/erc.11.152-s2.0-7995324683421438811
  20. M. Y. UmK. H. HwangJ. AhnT. Y. HaCurcumin attenuates diet-induced hepatic steatosis by activating AMP-activated protein kinaseBasic & Clinical Pharmacology & Toxicology2013113315215710.1111/bcpt.120762-s2.0-8488070229423574662
  21. J. M. LiY. C. LiL. D. KongQ. H. HuCurcumin inhibits hepatic protein-tyrosine phosphatase 1B and prevents hypertriglyceridemia and hepatic steatosis in fructose-fed ratsHepatology20105151555156610.1002/hep.235242-s2.0-7795142760520222050
  22. S. P. WeisbergR. LeibelD. V. TortorielloDietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesityEndocrinology200814973549355810.1210/en.2008-02622-s2.0-4634908879118403477
  23. L. I. RachekChapter eight—free fatty acids and skeletal muscle insulin resistanceProgress in Molecular Biology and Translational Science201412126729210.1016/B978-0-12-800101-1.00008-92-s2.0-8489671941124373240
  24. L. X. NaY. L. ZhangY. LiCurcumin improves insulin resistance in skeletal muscle of ratsNutrition, Metabolism & Cardiovascular Diseases201121752653310.1016/j.numecd.2009.11.0092-s2.0-7995950883220227862
  25. T. PollareB. VessbyH. LithellLipoprotein lipase activity in skeletal muscle is related to insulin sensitivityArteriosclerosis, Thrombosis, and Vascular Biology19911151192120310.1161/01.ATV.11.5.11921911706
  26. H. K. R. KarlssonJ. R. ZierathInsulin signaling and glucose transport in insulin resistant human skeletal muscleCell Biochemistry and Biophysics2007482-310311310.1007/s12013-007-0030-92-s2.0-3454831741917709880
  27. Y. T. DengT. W. ChangM. S. LeeJ. K. LinSuppression of free fatty acid-induced insulin resistance by phytopolyphenols in C2C12 mouse skeletal muscle cellsJournal of Agricultural and Food Chemistry20126041059106610.1021/jf204496f2-s2.0-8486306248622191431
  28. C. KangE. KimSynergistic effect of curcumin and insulin on muscle cell glucose metabolismFood and Chemical Toxicology2010488-92366237310.1016/j.fct.2010.05.0732-s2.0-7795505829420561944
  29. N. MaithilikarpagaselviM. G. SridharR. P. SwaminathanB. ZachariahCurcumin prevents inflammatory response, oxidative stress and insulin resistance in high fructose fed male Wistar rats: potential role of serine kinasesChemico-Biological Interactions201624418719410.1016/j.cbi.2015.12.0122-s2.0-8495268294326713546
  30. E. Lontchi-YimagouE. SobngwiT. E. MatshaA. P. KengneDiabetes mellitus and inflammationCurrent Diabetes Reports201313343544410.1007/s11892-013-0375-y2-s2.0-8487773193923494755
  31. A. M. GonzalesR. A. OrlandoCurcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytesNutrition & Metabolism200851p. 1710.1186/1743-7075-5-172-s2.0-4614910122418549505
  32. Y. CaoAngiogenesis and vascular functions in modulation of obesity, adipose metabolism, and insulin sensitivityCell Metabolism201318447848910.1016/j.cmet.2013.08.0082-s2.0-8488519020924035587
  33. A. EjazD. WuP. KwanM. MeydaniCurcumin inhibits adipogenesis in 3T3-L1 adipocytes and angiogenesis and obesity in C57/BL miceJournal of Nutrition2009139591992510.3945/jn.108.1009662-s2.0-6534918294019297423
  34. J. AhnH. LeeS. KimT. HaCurcumin-induced suppression of adipogenic differentiation is accompanied by activation of Wnt/β-catenin signalingAmerican Journal of Physiology-Cell Physiology20102986C1510C151610.1152/ajpcell.00369.20092-s2.0-7795261305920357182
  35. S. WangX. WangZ. YeCurcumin promotes browning of white adipose tissue in a norepinephrine-dependent wayBiochemical and Biophysical Research Communications2015466224725310.1016/j.bbrc.2015.09.0182-s2.0-8494229552926362189
  36. L. BestA. C. ElliottP. D. BrownCurcumin induces electrical activity in rat pancreatic β-cells by activating the volume-regulated anion channelBiochemical Pharmacology200773111768177510.1016/j.bcp.2007.02.0062-s2.0-3424712572917382910
  37. M. RouseA. YounèsJ. M. EganResveratrol and curcumin enhance pancreatic β-cell function by inhibiting phosphodiesterase activityJournal of Endocrinology2014223210711710.1530/JOE-14-03352-s2.0-8491575621825297556
  38. F. HaoJ. KangY. CaoCurcumin attenuates palmitate-induced apoptosis in MIN6 pancreatic β-cells through PI3K/Akt/FoxO1 and mitochondrial survival pathwaysApoptosis201520111420143210.1007/s10495-015-1150-02-s2.0-8494255123526330141
  39. L. DingJ. LiB. SongCurcumin rescues high fat diet-induced obesity and insulin sensitivity in mice through regulating SREBP pathwayToxicology and Applied Pharmacology20163049910910.1016/j.taap.2016.05.0112-s2.0-8497468791127208389
  40. A. ZieleniakM. WójcikL. A. WoźniakStructure and physiological functions of the human peroxisome proliferator-activated receptor γArchivum Immunologiae et Therapiae Experimentalis200856533134510.1007/s00005-008-0037-y2-s2.0-5384914929918836859
  41. M. A. El-MoselhyA. TayeS. S. SharkawiS. F. I. El-SisiA. F. AhmedThe antihyperglycemic effect of curcumin in high fat diet fed rats. Role of TNF-α and free fatty acidsFood and Chemical Toxicology20114951129114010.1016/j.fct.2011.02.0042-s2.0-7995303026621310207
  42. T. NishiyamaT. MaeH. KishidaCurcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay miceJournal of Agricultural and Food Chemistry200553495996310.1021/jf04838732-s2.0-1394426783015713005
  43. L. X. NaY. LiH. Z. PanCurcuminoids exert glucose-lowering effect in type 2 diabetes by decreasing serum free fatty acids: a double-blind, placebo-controlled trialMolecular Nutrition & Food Research20135791569157710.1002/mnfr.2012001312-s2.0-8488339962622930403
  44. L. X. NaB. L. YanS. JiangH. L. CuiY. LiC. H. SunCurcuminoids target decreasing serum adipocyte-fatty acid binding protein levels in their glucose-lowering effect in patients with type 2 diabetesBiomedical and Environmental Sciences2014271190290610.3967/bes2014.1272-s2.0-8492264762525374024
  45. H. R. RahimiA. H. MohammadpourM. DastaniThe effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trialAvicenna Journal of Phytomedicine20166556757727761427
  46. S. ChuengsamarnS. RattanamongkolgulR. LuechapudipornC. PhisalaphongS. JirawatnotaiCurcumin extract for prevention of type 2 diabetesDiabetes Care201235112121212710.2337/dc12-01162-s2.0-8486815002122773702
  47. T. YamauchiJ. KamonY. MinokoshiAdiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinaseNature Medicine20028111288129510.1038/nm7882-s2.0-003685181712368907
  48. D. HanahanR. A. WeinbergHallmarks of cancer: the next generationCell2011144564667410.1016/j.cell.2011.02.0132-s2.0-7995228412721376230
  49. G. HousmanS. BylerS. HeerbothDrug resistance in cancer: an overviewCancers2014641769179210.3390/cancers60317692-s2.0-8492308232425198391
  50. J. SunQ. WeiY. ZhouJ. WangQ. LiuH. XuA systematic analysis of FDA-approved anticancer drugsBMC Systems Biology201711S5p. 8710.1186/s12918-017-0464-72-s2.0-8503031853728984210
  51. A. B. KunnumakkaraD. BordoloiC. HarshaK. BanikS. C. GuptaB. B. AggarwalCurcumin mediates anticancer effects by modulating multiple cell signaling pathwaysClinical Science2017131151781179910.1042/CS201609352-s2.0-8502360395828679846
  52. J. KoffS. RamachandiranL. Bernal-MizrachiA time to kill: targeting apoptosis in cancerInternational Journal of Molecular Sciences201516122942295510.3390/ijms160229422-s2.0-8492202263425636036
  53. A. J. JiangG. JiangL. T. LiJ. N. ZhengCurcumin induces apoptosis through mitochondrial pathway and caspases activation in human melanoma cellsMolecular Biology Reports201542126727510.1007/s11033-014-3769-22-s2.0-8492193870725262359
  54. Y. LiS. ZhangJ. X. GengX. Y. HuCurcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome CAsian Pacific Journal of Cancer Prevention20131484599460210.7314/APJCP.2013.14.8.45992-s2.0-8488577963624083709
  55. M. YeJ. ZhangJ. ZhangQ. MiaoL. YaoJ. ZhangCurcumin promotes apoptosis by activating the p53-miR-192-5p/215-XIAP pathway in non-small cell lung cancerCancer Letters2015357119620510.1016/j.canlet.2014.11.0282-s2.0-8492047887425444916
  56. J. YangY. CaoJ. SunY. ZhangCurcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cellsMedical Oncology20102741114111810.1007/s12032-009-9344-32-s2.0-7995176790319908170
  57. W. F. HuaY. S. FuY. J. LiaoCurcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cellsEuropean Journal of Pharmacology20106371–3162110.1016/j.ejphar.2010.03.0512-s2.0-7795328949920385124
  58. M. BanerjeeP. SinghD. PandaCurcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cellsFEBS Journal2010277163437344810.1111/j.1742-4658.2010.07750.x2-s2.0-7795526143020646066
  59. C. P. PrasadG. RathS. MathurD. BhatnagarR. RalhanPotent growth suppressive activity of curcumin in human breast cancer cells: modulation of Wnt/β-catenin signalingChemico-Biological Interactions2009181226327110.1016/j.cbi.2009.06.0122-s2.0-6884908350419573523
  60. P. M. LiY. L. LiB. LiuW. J. WangY. Z. WangZ. LiCurcumin inhibits MHCC97H liver cancer cells by activating ROS/TLR-4/caspase signaling pathwayAsian Pacific Journal of Cancer Prevention20141552329233410.7314/APJCP.2014.15.5.23292-s2.0-8489909097624716979
  61. T. LiangX. ZhangW. XueS. ZhaoX. ZhangJ. PeiCurcumin induced human gastric cancer BGC-823 cells apoptosis by ROS-mediated ASK1-MKK4-JNK stress signaling pathwayInternational Journal of Molecular Sciences20141512157541576510.3390/ijms1509157542-s2.0-8490835114825198898
  62. Z. ChangJ. XingX. YuCurcumin induces osteosarcoma MG63 cells apoptosis via ROS/Cyto-C/Caspase-3 pathwayTumour Biology201435175375810.1007/s13277-013-1102-72-s2.0-8489450526123959480
  63. D. R. SiwakS. ShishodiaB. B. AggarwalR. KurzrockCurcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IκB kinase and nuclear factor κB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathwayCancer2005104487989010.1002/cncr.212162-s2.0-2344444984816007726
  64. F. CaoT. LiuY. XuD. XuS. FengCurcumin inhibits cell proliferation and promotes apoptosis in human osteoclastoma cell through MMP-9, NF-κB and JNK signaling pathwaysInternational Journal of Clinical and Experimental Pathology2015866037604526261481
  65. Y. GuoQ. ShanY. GongCurcumin induces apoptosis via simultaneously targeting AKT/mTOR and RAF/MEK/ERK survival signaling pathways in human leukemia THP-1 cellsPharmazie201469322923324716415
  66. J. RavindranS. PrasadB. B. AggarwalCurcumin and cancer cells: how many ways can curry kill tumor cells selectively?The AAPS Journal200911349551010.1208/s12248-009-9128-x2-s2.0-7334909498619590964
  67. R. K. Y. TsangW. W. Y. TangW. GaoCurcumin inhibits tongue carcinoma cells migration and invasion through downregulation of matrix metallopeptidase 10Cancer Investigation201230750351210.3109/07357907.2012.6911922-s2.0-8486397440622624612
  68. J. M. KimE. M. NohK. B. KwonCurcumin suppresses the TPA-induced invasion through inhibition of PKCα-dependent MMP-expression in MCF-7 human breast cancer cellsPhytomedicine201219121085109210.1016/j.phymed.2012.07.0022-s2.0-8486639431422921746
  69. N. MoZ. Q. LiJ. LiY. D. CaoCurcumin inhibits TGF-β1-induced MMP-9 and invasion through ERK and Smad signaling in breast cancer MDA-MB-231 cellsAsian Pacific Journal of Cancer Prevention201213115709571410.7314/APJCP.2012.13.11.57092-s2.0-8487402324123317243
  70. Q. ChenQ. GaoK. ChenY. WangL. ChenX. LiCurcumin suppresses migration and invasion of human endometrial carcinoma cellsOncology Letters20151031297130210.3892/ol.2015.34782-s2.0-8493742771026622667
  71. V. M. RadhakrishnanP. KojsG. YoungpTyr421 cortactin is overexpressed in colon cancer and is dephosphorylated by curcumin: involvement of non-receptor type 1 protein tyrosine phosphatase (PTPN1)PLoS One201491, article e8579610.1371/journal.pone.00857962-s2.0-8489985579924465712
  72. G. KumarS. MittalK. SakH. S. TuliMolecular mechanisms underlying chemopreventive potential of curcumin: current challenges and future perspectivesLife Sciences201614831332810.1016/j.lfs.2016.02.0222-s2.0-8495933511126876915
  73. N. DhillonB. B. AggarwalR. A. NewmanPhase II trial of curcumin in patients with advanced pancreatic cancerClinical Cancer Research200814144491449910.1158/1078-0432.CCR-08-00242-s2.0-5164911892818628464
  74. M. KanaiK. YoshimuraM. AsadaA phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancerCancer Chemotherapy and Pharmacology201168115716410.1007/s00280-010-1470-22-s2.0-7995961277220859741
  75. M. Bayet-RobertF. KwiatowskiM. LeheurteurPhase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancerCancer Biology & Therapy20109181410.4161/cbt.9.1.1039219901561
  76. H. MahammediE. PlanchatM. PougetThe new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II studyOncology2016902697810.1159/0004411482-s2.0-8497629120526771576
  77. A. GoelB. B. AggarwalCurcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organsNutrition and Cancer201062791993010.1080/01635581.2010.5098352-s2.0-7795801120920924967
  78. J. HejaziR. RastmaneshF. A. TalebanS. H. MolanaG. EhtejabA pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancerJournal of Cancer Science & Therapy201351032032410.4172/1948-5956.10002222-s2.0-84889654408
  79. J. L. RyanC. E. HecklerM. LingCurcumin for radiation dermatitis: a randomized, double-blind, placebo-controlled clinical trial of thirty breast cancer patientsRadiation Research20131801344310.1667/RR3255.12-s2.0-8488053217023745991
  80. G. GarceaD. J. L. JonesR. SinghDetection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administrationBritish Journal of Cancer20049051011101510.1038/sj.bjc.66016232-s2.0-464433260814997198
  81. Y. M. TsaiW. C. JanC. F. ChienW. C. LeeL. C. LinT. H. TsaiOptimised nano-formulation on the bioavailability of hydrophobic polyphenol, curcumin, in freely-moving ratsFood Chemistry2011127391892510.1016/j.foodchem.2011.01.0592-s2.0-7995253741425214079
  82. B. N. WaghelaA. SharmaS. DhumaleS. M. PandeyC. PathakCurcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cellsPLoS One2015102, article e011752610.1371/journal.pone.01175262-s2.0-8492328332925692854
  83. M. M. YallapuS. KhanD. M. MaherAnti-cancer activity of curcumin loaded nanoparticles in prostate cancerBiomaterials201435308635864810.1016/j.biomaterials.2014.06.0402-s2.0-8490473842125028336
The underlying source XML for this text is taken from The license for the article is Creative Commons Attribution 4.0 International. The main subject has been identified as maturity-onset diabetes of the young.